MacroGenics Adds Two Oncology Executives to Board
Small public biopharma companies are recruiting independent directors with late-stage and acquisition experience to strengthen governance.
Updated on Nov. 3, 2026 in People
MacroGenics, a Rockville, Maryland-based clinical-stage biopharmaceutical company focused on antibody-based cancer therapeutics, appointed Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., as independent directors to its Board of Directors, effective October 30, 2026. The company, which trades on NASDAQ under MGNX, announced the appointments on November 3, 2026.
Why it matters
Board additions with drug-development and commercial backgrounds signal how a small oncology developer is strengthening its governance as it advances antibody-based candidates. For operators in life sciences services, the appointments reflect a common pattern of recruiting directors with late-stage clinical and industry experience.
Vasconcelles brings approximately 35 years of experience across academic medicine, oncology, and executive leadership, while Kuriakose brings more than a decade of biopharmaceutical industry experience. The announcement does not disclose committee assignments or compensation for either director.
The players
MacroGenics, Inc.
A Rockville, Maryland clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics and listed on NASDAQ under MGNX.
Emil Kuriakose, M.D.
A biopharmaceutical executive who previously served as Chief Medical Officer of Terns Pharmaceuticals, bringing more than a decade of industry experience to the board.
Michael Vasconcelles, M.D.
A physician-executive with roughly 35 years across academic medicine, oncology, and leadership, formerly head of research and development at Day One Biopharmaceuticals.
The details
Emil Kuriakose most recently served as Chief Medical Officer of Terns Pharmaceuticals, which Merck acquired in 2026, giving him direct experience with late-stage development inside a company that was later absorbed by a major pharmaceutical buyer. Michael Vasconcelles previously led research and development at Day One Biopharmaceuticals and currently sits on the boards of Molecular Partners AG and Kura Oncology, Inc. Both are being added as independent directors, meaning they are not MacroGenics executives, which is the governance structure investors and boards typically look for in oversight roles.
Timeline
October 30, 2026: Board appointments of Kuriakose and Vasconcelles take effect.
November 3, 2026: MacroGenics announces the board appointments.
Market Landscape
Kuriakose's background at Terns, which Merck acquired in 2026, places him inside a recent large-pharma acquisition of a clinical-stage developer. MacroGenics is adding directors who have worked through that same consolidation path, from both the acquired-company and the acquirer-side development seats.
Operators in clinical-stage biotech and life sciences services should note that board recruitment is increasingly drawing on executives with completed late-stage and acquisition experience. Vendors and advisors serving small public biopharma companies may see governance-focused demand grow as boards add independent directors with industry depth.
The takeaway
Independent-director additions with late-stage and acquisition experience are a governance signal worth tracking for small public biopharma companies. Business owners in the sector should monitor subsequent MacroGenics filings for committee assignments and any changes in board composition.
Further reading
For more on the executives and governance moves shaping the sector, browse our People coverage.
Source note: This article includes information reported by The Manila times.
